



Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization

Stephan Windecker^{1*}, Franz-Josef Neumann², Peter Jüni³, Miguel Sousa-Uva^{4,5}, and Volkmar Falk^{6,7}

¹Department of Cardiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital University of Bern, Freiburgstrasse, 3006 Bern, Switzerland; ²Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany; ³Department of Medicine and Institute of Health Policy, Management and Evaluation, Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, 30 Bond St, ON M5B 1W8, Toronto, Canada; ⁴Department of Cardiac Surgery, Hospital Santa Cruz, Av. Prof. Dr. Reinaldo dos Santos 2790-134, Carnaxide, Portugal; ⁵Cardiovascular R&D Unit, Department of Cardiothoracic Surgery, Porto University, Porto, Portugal; ⁶Department of Cardiothoracic and Vascular Surgery, German Heart Center, Augustenburger, Platz 1, Berlin, D-133353, Germany; and ⁷Department of Cardiovascular Surgery, Charite Berlin, Charite platz 1, D-10117 Berlin, Germany

Received 3 July 2018; revised 23 July 2018; editorial decision 8 August 2018; accepted 9 August 2018; online publish-ahead-of-print 25 August 2018

The 2018 ESC/EACTS guidelines on myocardial revascularization reflect the joint effort of the European Society of Cardiology (ESC) and the European Association of Cardiothoracic Surgery (EACTS) to provide up-to-date recommendations that are both evidence-based and clinically meaningful. Although the field of myocardial revascularization represents one of the best studied therapeutic technical interventions in medicine with >20 randomized clinical trials (RCT) comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) enrolling approximately 15 000 patients, there remain areas of controversy owing to imperfect or incomplete data that have accumulated over time. One of the major points of discussion surround the issue of choosing between the revascularization strategies based on clinically relevant subsets.


The appropriate treatment allocation among patients with left main and coronary artery disease (CAD) at estimated low surgical risk remains a complex decision process. It is best achieved in the context of the local Heart Team taking into consideration the operative risk as calculated by established risk scores, the complexity of the underlying CAD, intra- and extracardiac factors that may favour one

revascularization technique over another as well as local expertise. The 2018 ESC/EACTS guidelines on myocardial revascularization recommend the use of the STS score (Class IB) or EuroSCORE II (IIb B) to estimate in-hospital CABG-related mortality,^{1–3} the calculation of the Syntax score (Class IB) to assess anatomical complexity as well as the long-term risk of mortality and morbidity after PCI,^{4–9} and emphasize the importance to achieve complete revascularization (Class IIa B) when considering the revascularization options.^{10–13} In the absence of an accepted cut-off to define low surgical mortality, the 2018 ESC/EACTS guidelines advise individual decision taking and refer to the estimated risk that has been reported in major trial comparing PCI and CABG. A table to inform the reader is provide in Chapter 5.3.1.1 of the guideline document.¹⁴

The stratification of guideline recommendations between CABG and PCI in patients with stable multivessel CAD according to anatomical complexity with use of the SYNTAX score groups, diabetes, and left main disease was introduced in the 2010 ESC/EACTS Guidelines on Myocardial Revascularization¹⁵ and maintained in the 2014 version.¹⁶ Of note, the ACCF/AHA/SCAI 2011 guideline for

* Corresponding author. Tel: +41 31 632 4497, Fax: +41-31-632 4771, Email: stephan.windecker@insel.ch

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.



PCIs¹⁷ and American College of Cardiology (ACC)/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria¹⁸ have embraced the same criteria for stratification of treatment decisions on CABG vs. PCI. Here, we will review the rationale and new evidence in support of this stratification scheme (*Take home figure*). We also point to the lack of acceptable alternative stratification systems since none of them have been investigated in prospective studies. This article is a companion article to the 2018 ESC/EACTS guidelines on myocardial revascularization expanding on details that are introduced in the chapter revascularization in stable CAD.¹⁴

Anatomical complexity of multivessel coronary artery disease and SYNTAX score

Ample evidence from observational and controlled studies indicate that extent and severity of coronary artery stenoses impact prognosis. The seminal individual patient data meta-analysis of seven RCTs comparing CABG with medical therapy by Yusuf *et al.*¹⁹ firmly established a survival benefit of surgical revascularization over medical therapy. Of note, the relative benefit of CABG over medical therapy increased according to disease severity being greatest among patients with left main, intermediate among patients with three-vessel and least among patients with one- or two-vessel CAD.

In 2007, Bravata *et al.*²⁰ reported the results of a meta-analysis of 23 RCTs comparing CABG and PCI (balloon angioplasty and bare

metal stents) among approximately 10 000 patients. The data showed similar survival throughout 10 years, but a higher risk of stroke, better relief of angina, and a lower risk of repeat revascularization with CABG. The failure to demonstrate significant differences in terms of survival during long-term follow-up was thought to be related to the fact that these trials included highly selected patients (10% of screened patients) and excluded patients with complex and advanced CAD (three-vessel or left main disease). In contrast, several non-randomized observational studies comparing CABG and PCI using large health record data sets reported better survival with CABG than PCI in the overall cohort with subgroup analyses suggesting a gradient of benefit particularly among patients with three-vessel disease.^{21–25}

The SYNTAX trial was the first multicentre RCT comparing CABG with PCI using drug-eluting stents (DES) that employed a heart-team based, all-comer approach, and succeeded to include 41% of screened patients increasing its external validity.²⁶ All patients were required to have severe CAD by limiting inclusion to patients with three-vessel and left main CAD. Of note, it prospectively validated the SYNTAX score, an angiography based index of anatomical complexity among patients with multivessel and left main disease using evaluation by an independent core laboratory.

The SYNTAX score had not been derived from a specific data set, but rather developed by an international group of expert cardiac surgeons and interventional cardiologists in an effort to optimize several previously proposed CAD scoring systems including the American Heart Association (AHA) classification modified for the ARTS (Arterial Revascularization Therapy Study) study, the Leaman score,




Figure 1 All-cause mortality among patients with multivessel and left main coronary artery disease (All) and separate for multivessel coronary artery disease and left main coronary artery disease stratified by SYNTAX score. Data [rates, hazard ratios (HR), 95% confidence intervals (CI), and P-values] are derived from the individual-patient data meta-analysis by Head et al.²⁹

the ACC/AHA lesion classification system, the total occlusion classification system, and the Duke and ICPS classification systems for bifurcation lesions. Assuming that the number of diseased vessels was not the only marker for CAD severity, the SYNTAX score systematically addressed other lesion-based factors including the location of lesions, the degree of coronary stenosis, calcification, the specific complexity of left main, bifurcations, total occlusions, thrombus, and small vessels.²⁷ The SYNTAX score was first validated in the ARTS II study showing that the lowest SYNTAX tertile was associated with significantly higher freedom from major adverse cardiac events than the intermediate and high SYNTAX tertiles.²⁸ In multivariable analyses, the SYNTAX score emerged as independent predictor of MACE at 5 years suggesting a potential role of baseline assessment of the SYNTAX score in the risk stratification of patients undergoing PCI. Moreover, it proved superior in terms of long-term outcome prediction compared with the traditional ACC/AHA classification system.

Results of the SYNTAX trial at 1 and 5 years failed to demonstrate non-inferiority of PCI compared with CABG for the primary composite endpoint of major adverse cardiac and cerebrovascular events (MACCE).^{8,26} However, pre-specified subgroup analyses of the primary endpoint MACCE according to SYNTAX tertiles stratified according to low (0–22), intermediate (23–32), and high (>32) SYNTAX tertiles showed that the relative efficacy of CABG over PCI was dependent on anatomical complexity of CAD with a significant P-value for interaction.²⁶ Accordingly, the SYNTAX score as angiographic marker of anatomical disease complexity was associated with a significant interaction effect on clinical outcomes for PCI (predictive) but not CABG (not predictive). The statistical analysis plan of the SYNTAX trial implemented a hierarchical approach whereby subgroup analyses would only be allowed if the primary endpoint would be met. From a statistical point of view, the stratified outcome

analysis of the SYNTAX trial was therefore formally hypothesis generating. Of note, the American Food and Drug Administration (FDA) subsequently adopted the SYNTAX score to define inclusion criteria for trials comparing PCI and CABG.

Recently, Head et al.²⁹ reported the results of a collaborative individual patient data meta-analysis of 11 RCTs among 11 518 patients with multivessel or left main CAD who did not present with acute coronary syndromes and were randomly allocated to CABG or PCI with the primary outcome all-cause mortality. Results in the overall group of patients with multivessel or left main CAD demonstrated superiority of CABG over PCI for all-cause mortality during a mean follow-up of 3.8 ± 1.4 years. Stratified analyses according to SYNTAX score confirmed a gradient of benefit between PCI and CABG across SYNTAX tertiles with similar mortality among patients with low SYNTAX score (8.8% vs. 8.1%, $P=0.91$) but increased rates of mortality among patients treated by PCI in the intermediate (12.4% vs. 10.9%, $P=0.14$) and high SYNTAX tertiles (16.5% vs. 11.6%, $P=0.003$) (Figure 1).

There were formally negative tests for interaction between subgroups of patients with low, moderate, or high SYNTAX scores and hazard ratios (HRs) of death. However, the investigators tested for subgroup by treatment interactions across unordered subgroups defined by SYNTAX tertiles, even though the clinically most plausible hypothesis is that HRs comparing CABG with PCI will increase with increasing SYNTAX tertiles. This hypothesis can be examined in a test for linear trend of log HRs across ordered SYNTAX tertiles.³⁰ Head et al. performed such a test for linear trend of log HRs across ordered SYNTAX tertiles using the same approach as for the primary analysis, a random-effects Cox model with shared frailty reflected by a random intercept to account for variation in baseline risk between trials. This test for trend of HRs of death across

ordered SYNTAX tertiles was positive in the overall population at $P=0.00114$ and positive for the population with multivessel disease (in the absence of left main disease) at $P=0.00055$. These data therefore also satisfy statistical criteria of significance for the interaction between SYNTAX tertiles and outcomes between PCI and CABG.

Based on the review above, the SYNTAX score currently remains the best tool to gauge the anatomical complexity of advanced CAD and is helpful to appraise the relative benefit of choosing between revascularization strategies among patients with multivessel disease. Despite its proven validity, the SYNTAX score cannot prevail as the sole criterion for decision making on the revascularization strategy. Apart from anatomical complexity a number of clinical characteristics that modify the peri-operative and peri-interventional risk need to be considered. To account for this, several risk scores combining clinical variables with the SYNTAX score have been developed. Yet, none of these scores have been validated in a prospective study. Among them, the SYNTAX II score is the most intensively studied. The SYNTAX II score was derived retrospectively from the SYNTAX cohort and was subsequently externally validated in several pre-existing cohorts.^{7,31–33} Although discrimination and calibration were mostly adequate in these analyses, the SYNTAX II score failed to predict the outcome in the surgical arm of EXCEL. In aggregate, there is currently no sufficiently validated score that combines anatomical complexity with relevant clinical variables.

In summary, the SYNTAX score remains the best tool to guide evidence-based decisions on the revascularization strategy (*Take home figure* and *Figure 1*). With low SYNTAX scores PCI and CABG achieve similar long-term outcomes with respect to survival and the composite of death, myocardial infarction (MI), and stroke. Thus, PCI may be preferred as the more convenient and less resource-consuming treatment modality. Conversely, in patients with intermediate or high SYNTAX score, the lower mortality after CABG in conjunction with lower incidence of MI precludes PCI as an alternative to CABG in patients who are good surgical candidates.

Left main disease

Left main CAD has been recognized as specific disease entity since its first description by Herrick and the advent of coronary angiography in the 1960s^{34–36} and is observed in 4–7% of patients undergoing diagnostic coronary angiography.³⁷ Due to its proximal location in the coronary artery tree, lesions of the left main may jeopardize blood flow subtending up to 60–90% of the myocardium. There are also important anatomico-pathological considerations owing to the differences between aorto-ostial lesions and the distal left main with involvement of the bifurcation in >60% of cases.

The first RCTs comparing CABG with medical therapy observed a survival benefit in favour of revascularization, findings that were synthesized in the individual patient data meta-analysis by Yusuf *et al.*¹⁹ reporting the greatest relative benefit of CABG over medical therapy in the specific subset of patients with left main disease. Since then, it has been generally accepted that patients with left main disease should undergo expeditious revascularization by CABG, a recommendation that was sustained in guidelines over years as untreated left main disease is associated with poor prognosis.^{26,38,39}

While PCI of left main disease was regarded contraindicated during the balloon angioplasty era, the advent of stents led to several dedicated RCTs assessing PCI in the specific setting of patients with left main disease.^{40–43} Two recent RCTs compared PCI with the use of new generation DES and CABG in the specific setting of left main disease. The EXCEL trial compared CABG with PCI using new generation DES [Everolimus-Eluting Stent (EES)] among 1905 patients with left main CAD with evidence of invasive or non-invasive ischaemia.⁴² Although complex left main CAD defined as SYNTAX score of >32 constituted a formal exclusion criterion, the distribution of SYNTAX score tertiles according to the Core laboratory evaluation were 36%, 40%, and 24% for low (<22), intermediate (23–32), and high (>32) SYNTAX score, respectively. At 3 years of follow-up, the primary endpoint of death, stroke, or MI occurred with similar frequency in the CABG and PCI group [14.7% vs. 15.4%, HR 1.00, 95% confidence interval (CI) 0.79–1.26; $P=0.98$] without significant differences in the individual components. Repeat revascularization (which unlike in previous trials was not included as an endpoint in the MACE analysis) was less common with CABG than PCI (12.9% vs. 7.6%, $P<0.001$). The trial used as definition of peri-procedural (within 72 h of the procedure) MI an increase in CK-MB >10 upper limit of normal (ULN) or CK-MB >5ULN in the presence of angiographically documented graft/stent occlusion, new pathological Q-waves in 2 contiguous leads or imaging evidence of new loss of viable myocardium. Peri-procedural MI was recorded in 3.6% of patients undergoing PCI and 5.9% of patients undergoing CABG (HR 0.61, 95% CI 0.40–0.93; $P=0.02$) and ST-segment-elevation MI was noted in 0.7% of patients undergoing PCI and 2.3% of patients undergoing CABG within 30 days of the procedure (HR 0.32, 95% CI 0.14–0.74, $P=0.005$). As a result, the primary endpoint within 30 days was in favour of PCI (4.9% vs. 7.9%, HR 0.61, 95% CI 0.42–0.88; $P=0.008$). However, CABG was associated with a trend towards fewer spontaneous MIs throughout 3 years (4.3% vs. 2.7%, $P=0.07$) and the preplanned landmark analysis from 30d to 3 years showed a significant difference for the primary endpoint in favour of surgery (7.9% vs. 11.5%, $P=0.02$).

The NOBLE trial compared CABG with PCI using new generation DES (Biolimus-Eluting Stent-BES) among 1201 patients with left main CAD (mean SYNTAX score of 23) treated between 2008 and 2015.⁴³ At a median follow-up of 3.1 years, the primary endpoint of death, non-procedural MI, stroke and repeat revascularization occurred more frequently in the PCI than CABG group (29% vs. 19%, HR 1.48, 95% CI 1.11–1.96; $P=0.007$). While there were no differences in the incidence of all-cause and cardiac death, PCI was associated with a higher incidence of non-procedural MI (7% vs. 2%, $P=0.004$) and repeat revascularization (16% vs. 10%, $P=0.03$). The trial failed to demonstrate non-inferiority of PCI for the primary endpoint and CABG was found superior to PCI ($P=0.0066$).

The most recent synthesis of available evidence stems from the individual patient pooled analysis by Head *et al.* including 4478 patients with left main CAD randomly assigned to CABG or PCI with a mean follow-up of 3.4 ± 1.4 years.²⁹ The authors reported similar risks for the primary outcome all-cause mortality (PCI: 10.7% vs. CABG 10.5%, HR 1.07, 95% CI 0.87–1.33; $P=0.52$) throughout 5 years.²⁹ There were no significant differences in mortality between PCI and CABG in subgroup analyses according to SYNTAX score (*Figure 1*). Although the proportion of patients with high SYNTAX score was limited in view of the inclusion criteria of the respective studies, there

was a trend towards better survival with CABG in this subset (P for trend 0.064). Of note, considering life expectancy of patients included in the latest trials investigating revascularization in the setting of left main CAD, longer follow-up results of these trials are awaited.

Based on the available evidence as established in dedicated RCTs and the distinct anatomico-pathophysiological properties of this lesion, left main CAD needs to be considered as a separate clinical and anatomical entity in practice guidelines.

Synthesis of the available evidence suggests that PCI is an appropriate alternative to CABG in left main CAD (*Take home figure* and *Figure 1*) Among patients with low to intermediate complexity left main CAD, clinical outcomes with respect to major adverse cerebrovascular events and ischaemic endpoints are similar for PCI and CABG and both revascularization strategies can be considered in this patient population. Conversely, the number of patients with high complexity studied in RCTs is low due to exclusion criteria and the risk estimates and CIs remain imprecise. Therefore, PCI in this setting cannot be endorsed as long-term outcomes are likely to be similar to patients with multivessel disease. With an increasing extent of the underlying CAD CABG is hence likely to provide improved long-term outcomes in patients with left main CAD.

Diabetes mellitus

Diabetes mellitus is not just a risk factor but rather a distinct disease entity that is critical for the selection between myocardial revascularization strategies in patients with multivessel disease. Diabetes mellitus, which is observed in 20–30% of patients requiring revascularization, is associated with systemic endothelial dysfunction, accelerated atherosclerosis and more diffuse pattern of CAD.^{44,45} These disease properties are associated with a more pronounced progression of CAD after revascularization as well as neointimal

hyperplastic response after PCI and may explain at least in part the differences in outcomes between CABG and PCI in patients with diabetes and multivessel CAD as compared to patients without diabetes.

The randomized BARI trial comparing PCI with use of balloon angioplasty and CABG in selected patients with multivessel CAD reported similar mortality for both revascularization strategies at 5 and 10 years.^{46,47} In 1992, the Data Safety and Monitoring Board recommended to monitor outcomes among diabetic patients, a subgroup that had not been *a priori* defined as subgroup in the original protocol. Stratified analyses according to diabetes mellitus revealed improved survival among patients allocated to CABG compared with those allocated to PCI at 5 years and 10 years of follow-up. Conversely, in the SYNTAX trial stratified analyses of primary and secondary outcomes according to diabetic status did not reveal a relevant interaction⁴⁸ although event rates were consistently higher among patients with diabetes.

In 2009, Hlatky *et al.*⁴⁹ reported the results of an individual patient data meta-analysis of 10 RCTs (6 RCTs with balloon angioplasty, 4 RCTs with bare metal stents) including 7812 patients comparing PCI and CABG among patients with multivessel CAD with a mean follow-up of 5.9 years. In stratified analyses according to diabetes status, a significant interaction ($P = 0.014$) by treatment modality was identified with substantially higher mortality among patients with diabetes allocated to PCI (20% vs. 12.3%; HR 0.70, 95% CI 0.56–0.87), whereas mortality was similar for PCI and CABG among patients without diabetes (8.1% vs. 7.6%; HR 0.98, 95% CI 0.86–1.12).

In the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial, the largest randomized study in diabetics, PCI with use of early-generation DES was compared with CABG in diabetic patients undergoing elective revascularization for multivessel CAD.⁵⁰




Figure 2 All-cause mortality among patients with multivessel and left main coronary artery disease (All) and separate for multivessel coronary artery disease and left main coronary artery disease stratified by diabetes mellitus. Data [rates, hazard ratios (HR), 95% confidence intervals (CI) and P -values] are derived from the individual-patient data meta-analysis by Head *et al.*²⁹

Out of a total of 33 966 patients screened, 1900 patients (6%) with a mean SYNTAX score of 26 ± 9 were enrolled. During 5-year follow-up, CABG significantly reduced the risk of the primary endpoint death, MI, or stroke compared with PCI. Consistent with the reports above, the individual patient data meta-analysis of 11 RCTs by Head *et al.*²⁹ reported a significant interaction by revascularization allocation in stratified analysis according to diabetes mellitus. In patients with diabetes, mortality was higher among patients allocated to PCI compared with CABG (15.7% vs. 10.7%, HR 1.44, 95% CI 1.20–1.74; $P = 0.001$), whereas mortality was comparable for PCI and CABG among patients without diabetes (8.7% vs. 8.2%, HR 1.02, 95% CI 0.86–1.21; $P = 0.81$, P for interaction 0.0077, Figure 2).

It has been argued that the P -value for interaction in the work by Head *et al.* would have to be adjusted for multiple testing, resulting in an adjusted P -value for significance of 0.005 based on the 10 comparisons reported in the original publication. However, only three of the subgroup analyses, namely diabetes status, tertiles of SYNTAX score, and left main disease would be considered key interactions and primary in nature, backed by prior pathophysiological, clinical and/or anatomical concepts, while the other subgroup analyses with interaction tests would be considered hierarchically subordinate and secondary in nature.

Thus, based on current evidence diabetes mellitus is the strongest predictor of a survival benefit of CABG as compared with PCI in patients with multivessel CAD. Particularly, in patients with intermediate or high SYNTAX scores this survival benefit is substantial and considerably more pronounced than in the absence of diabetes. Only, with low SYNTAX score it may be justified to consider PCI as an alternative to CABG (*Take home figure*).

Future perspective

Revascularization aims to improve myocardial blood flow thereby reducing ischaemia.⁵¹ An important pre-requisite to achieve this goal is the comprehensive assessment and treatment planning of lesions requiring revascularization including treatment optimization. Although anatomical classification of CAD extent has been the foundation to guide revascularization and risk stratification among patients with multivessel CAD, intracoronary physiology-derived parameters [fractional flow reserve (FFR) and instantaneous wave-free ratio (iwFR)] provide incremental value by virtue of lesion reclassification^{52–54} resulting in both deferral of intervention or identification of previously unrecognized ischaemia-producing lesions. Moreover, complete anatomical and physiological revascularization among patients with multivessel CAD is associated with improved outcomes irrespective of the revascularization strategy but has been less complete in case of PCI particularly among patients with chronic total occlusions (CTO).^{10,11,13,55} In addition, pre-interventional physiologic lesion mapping⁵⁶ and intracoronary imaging (intravascular ultrasound (IVUS) and optical coherence tomography (OCT))^{57–60} as well as post-procedural assessment translate into improved outcomes particularly among patients with left main and multivessel disease. Of note, none of the intracoronary physiology or imaging parameters have been prospectively investigated in trials comparing PCI and CABG and represent an important gap of evidence. Notwithstanding, observational data from the recent SYNTAX II trial indicate that a multimodal strategy incorporating guideline-based

medical treatment, a heart-team based patient selection with use of the SYNTAX score II, intracoronary physiology-guided PCI using a hybrid assessment using iwFR and FFR combined with IVUS-guided stent implantation and contemporary CTO lesion management result in improved clinical outcomes throughout 1 year as compared to a historical PCI cohort derived from the SYNTAX I trial.⁶¹ These procedural and technological improvements deserve consideration and further evaluation in appropriately designed revascularization trials.

Summary

Myocardial revascularization as adjunct to guideline-based medical therapy remains the mainstay in the treatment of patients with symptomatic or ischaemia-producing CAD. Patients with left main and multivessel CAD require individual decision making by the local Heart Team guided by assessment of the operative risk, complexity of the underlying CAD, and likelihood to achieve complete revascularization. The choice between PCI and CABG is informed by carefully weighing the benefits and risks inherent to the respective revascularization technique as well as local expertise. The SYNTAX score remains the best tool to guide decisions on the revascularization strategy among patients with multivessel CAD complemented by considerations in the presence of left main CAD and diabetes.

Conflict of interest: Dr Windecker reports grants from Amgen, grants from Abbott, grants from Bayer, grants from Biotronik, grants from Boston Scientific, grants from Medtronic, grants from Edwards Lifesciences, grants from St Jude, grants from Terumo, outside the submitted work; Dr Neumann reports grants from Biotronik, grants from Edwards Lifesciences, grants from Medtronic, grants from Bayer Healthcare, grants from Abbott Vascular, grants from Novartis, grants from Pfizer, grants from GlaxoSmithKline, outside the submitted work; Dr Sousa-Uva reports personal fees from Abbott, outside the submitted work; Dr Falk reports research and study funds from Biotronik, Boston Scientific, Berlin Heart, Novartis, and grant support including travel support from Abbott, Medtronic, Edwards Lifesciences, and advisory board member of Medtronic, Berlin Heart, Novartis, Boston Scientific Dr Peter Jüni is a Tier 1 Canada Research Chair in Clinical Epidemiology of Chronic Diseases, this research was completed, in part, with funding from the Canada Research Chairs Programme. Peter Jüni serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company.

References

- Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, Rich JB. Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. *Eur J Cardiothorac Surg* 2014;**46**:400–408; discussion 408.
- Kirmani BH, Mazhar K, Fabri BM, Pullan DM. Comparison of the EuroSCORE II and Society of Thoracic Surgeons 2008 risk tools. *Eur J Cardiothorac Surg* 2013; **44**:999–1005; discussion 1005.
- Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of EuroSCORE II, Original EuroSCORE, and the Society of Thoracic Surgeons Risk Score in Cardiac Surgery Patients. *Ann Thorac Surg* 2016;**102**:573–579.
- Wykrzykowska JJ, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, Buszman P, Linke A, Ischinger T, Klaus V, Corti R, Eberli F, Wijns W, Morice MC, di

- Mario C, van Geuns RJ, Juni P, Windecker S, Serruys PW. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. *J Am Coll Cardiol* 2010;**56**:272–277.
5. Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. *JACC Cardiovasc Interv* 2011;**4**:432–441.
 6. Zhao M, Stampf S, Valina C, Kienzle RP, Ferenc M, Gick M, Essang E, Nuhrenberg T, Buttner HJ, Schumacher M, Neumann FJ. Role of euroSCORE II in predicting long-term outcome after percutaneous catheter intervention for coronary triple vessel disease or left main stenosis. *Int J Cardiol* 2013;**168**:3273–3279.
 7. Cavalcante R, Sotomi Y, Mancone M, Whan Lee C, Ahn JM, Onuma Y, Lemos PA, van Geuns RJ, Park SJ, Serruys PW. Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. *Eur Heart J* 2017;**38**:1969–1977.
 8. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013;**381**:629–638.
 9. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR, Choi JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. *Circulation* 2014;**129**:2388–2394.
 10. Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV, Holmes DR, Mack M, Feldman T, Morice MC, Stahle E, James S, Colombo A, Diletti R, Papafakis MI, de Vries T, Morel MA, van Es GA, Mohr FW, Dawkins KD, Kappetein AP, Sianos G, Boersma E. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. *J Am Coll Cardiol* 2013;**61**:282–294.
 11. Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D, Brilakis ES. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. *J Am Coll Cardiol* 2013;**62**:1421–1431.
 12. Ahn JM, Park DW, Lee CW, Chang M, Cavalcante R, Sotomi Y, Onuma Y, Tenekecioglu E, Han M, Lee PH, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ. Comparison of stenting versus bypass surgery according to the completeness of revascularization in severe coronary artery disease: patient-level pooled analysis of the SYNTAX, PRECOMBAT, and BEST trials. *JACC Cardiovasc Interv* 2017;**10**:1415–1424.
 13. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation* 2013;**128**:141–151.
 14. 2018 ESC/EACTS Guidelines on myocardial revascularization - Supplementary Data: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Cardio-Thoracic Surgery (EACTS). Authors/Task Force Members: Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. *Eur Heart J* 2019;**40**:87–165.
 15. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schlij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Kolh P, Alfieri O, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouhe P, Kearney P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, Brutel de la Riviere A, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SAM, Neumann F-J, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M. Guidelines on myocardial revascularization. *Eur Heart J* 2010;**31**:2501–2555.
 16. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;**35**:2541–2619.
 17. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol* 2011;**58**:2550–2122.
 18. Patel MR, Calhoun JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2017;**69**:2212–2241.
 19. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet* 1994;**344**:563–570.
 20. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. *Ann Intern Med* 2007;**147**:703–716.
 21. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, Helm RE, Kellett MA, Dauerman HL, Dacey LJ, Silver MT, VerLee PN, Weldner PW, Hettleman BD, Olmstead EM, Piper WD, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation* 2005;**112**(9 Suppl):I371–I376.
 22. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med* 2005;**352**:2174–2183.
 23. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med* 2008;**358**:331–341.
 24. Weintraub B. Comparative effectiveness of revascularization strategies. *N Engl J Med* 2012;**366**:83–76.
 25. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. *N Engl J Med* 2015;**372**:1213–1222.
 26. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;**360**:961–972.
 27. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention* 2005;**1**:219–227.
 28. Valgimigli M, Serruys PW, Tsuchida K, Vaina S, Morel MA, van den Brand MJ, Colombo A, Morice MC, Dawkins K, de Bruyne B, Kornowski R, de Servi S, Guagliumi G, Jukema JW, Mohr FW, Kappetein AP, Wittebols K, Stoll HP, Boersma E, Parrinello G; ARTS II. Cyphering the complexity of coronary artery disease using the SYNTAX score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. *Am J Cardiol* 2007;**99**:1072–1081.
 29. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamlesh M, Kim YH, Makikallio T, Mohr FW, Papageorgiou G, Park SJ,

- Rodriguez AE, Sabik JF 3rd, Stables RH, Stone GW, Serruys PW, Kappetein AP. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet* 2018;**391**:939–948.
30. Jüni P, Windecker S, Neumann FJ. Interpretation of results of pooled analysis of individual patient data. *Lancet* (in press).
 31. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Stahle E, Onuma Y, Morel MA, Garcia-Garcia HM, van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet* 2013;**381**:639–650.
 32. Campos CM, Garcia-Garcia HM, van Klaveren D, Ishibashi Y, Cho YK, Valgimigli M, Raber L, Jonker H, Onuma Y, Farooq V, Garg S, Windecker S, Morel MA, Steyerberg EW, Serruys PW. Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: a patient-level pooled analysis of 5,433 patients enrolled in contemporary coronary stent trials. *Int J Cardiol* 2015;**187**:111–115.
 33. Sotomi Y, Cavalcanti R, van Klaveren D, Ahn JM, Lee CW, de Winter RJ, Wykrzykowska JJ, Onuma Y, Steyerberg EW, Park SJ, Serruys PW. Individual long-term mortality prediction following either coronary stenting or bypass surgery in patients with multivessel and/or unprotected left main disease: an external validation of the SYNTAX Score II Model in the 1,480 patients of the BEST and PRECOMBAT randomized controlled trials. *JACC Cardiovasc Interv* 2016;**9**:1564–1572.
 34. Herrick JB. Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. By James B. Herrick. *JAMA* 1983;**250**:1757–1765.
 35. Isner JM, Kishel J, Kent KM, Ronan JA Jr, Ross AM, Roberts WC. Accuracy of angiographic determination of left main coronary arterial narrowing. Angiographic–histologic correlative analysis in 28 patients. *Circulation* 1981;**63**:1056–1064.
 36. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, Taylor HA, Chaitman BR. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. *Circulation* 1995;**91**:2325–2334.
 37. Bing R. Percutaneous transcatheter assessment of the left main coronary artery: current status and future directions. *JACC Cardiovasc Imaging* 2015;**15**:1529–1539.
 38. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug J-E, Ruzyllo W, Urban P, Stone GW, Wijns W. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. *Eur Heart J* 2005;**26**:804–847.
 39. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology/American Heart Association Task Force on Practice Guidelines: ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). *J Am Coll Cardiol* 2006;**47**:e1–e121.
 40. Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR, Torracca L, van Es GA, Leadley K, Dawkins KD, Mohr F. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation* 2010;**121**:2645–2653.
 41. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Chung CH, Lee JW, Lim DS, Rha SW, Lee SG, Gwon HC, Kim HS, Chae IH, Jang Y, Jeong MH, Tahk SJ, Seung KB. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med* 2011;**364**:1718–1727.
 42. Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice M-C, Lembo N, Brown WM, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Nioxens N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *N Engl J Med* 2016;**375**:2223–2235.
 43. Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman A, Cotton J, Eriksen E, Margus S, Sorensen HT, Nielsen PH, Niemela M, Kervinen K, Lassen JF, Maeng M, Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Frobert O, Graham AN, Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *Lancet* 2016;**388**:2743–2752.
 44. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. *Circulation* 2003;**108**:1655–1661.
 45. Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. *Rev Endocr Metab Disord* 2010;**11**:75–86.
 46. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;**335**:217–225.
 47. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 2007;**49**:1600–1606.
 48. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg* 2013;**43**:1006–1013.
 49. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;**373**:1190–1197.
 50. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;**367**:2375–2384.
 51. Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularisation and invasive strategies. *Lancet* 2015;**386**:702–713.
 52. Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, Champagne S, Belle L, Barreau D, Hanssen M, Besnard C, Dauphin R, Dallongeville J, El Hahi Y, Sideris G, Bretelle C, Lhoest N, Barnay P, Leborgne L, Dupouy P; Investigators of the Registre Français de la FFR-R3F. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. *Circulation* 2014;**129**:173–185.
 53. Curzen N, Rana O, Nicholas Z, Golledge P, Zaman A, Oldroyd K, Hanratty C, Banning A, Wheatcroft S, Hobson A, Chitkara K, Hildick-Smith D, McKenzie D, Calver A, Dimitrov BD, Corbett S. Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain? The RIPCORD study. *Circ Cardiovasc Interv* 2014;**7**:248–255.
 54. Baptista SB, Raposo L, Santos L, Ramos R, Cale R, Jorge E, Machado C, Costa M, Infante de Oliveira E, Costa J, Pipa J, Fonseca N, Guardado J, Silva B, Sousa MJ, Silva JC, Rodrigues A, Seca L, Fernandes R. Impact of routine fractional flow reserve evaluation during coronary angiography on management strategy and clinical outcome: one-year results of the POST-IT. *Circ Cardiovasc Interv* 2016;**9**:e003288.
 55. Zimarino M, Ricci F, Romanello M, Di Nicola M, Corazzini A, De Caterina R. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: a meta-analysis of randomized and observational studies. *Catheter Cardiovasc Interv* 2016;**87**:3–12.
 56. Echavarría-Pinto M, Collet C, Escaned J, Piek JJ, Serruys PW. State of the art: pressure wire and coronary functional assessment. *EuroIntervention* 2017;**13**:666–679.
 57. Casella G, Klaus V, Ottani F, Siebert U, Sangiorgio P, Bracchetti D. Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. *Catheter Cardiovasc Interv* 2003;**59**:314–321.
 58. Witzensbichler B, Maehara A, Weisz G, Neumann FJ, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Stuckey TD, Mazzaferri EL Jr, Xu K, Parise H, Mehran R, Mintz GS, Stone GW. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. *Circulation* 2014;**129**:463–470.
 59. Maehara A, Ben-Yehuda O, Ali Z, Wijns W, Bezerra HG, Shite J, Genereux P, Nichols M, Jenkins P, Witzensbichler B, Mintz GS, Stone GW. Comparison

- of stent expansion guided by optical coherence tomography versus intravascular ultrasound: the ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention). *JACC Cardiovasc Interv* 2015;**8**: 1704–1714.
60. Park SJ, Kim YH, Park DW, Lee SW, Kim WJ, Suh J, Yun SC, Lee CW, Hong MK, Lee JH, Park SW; MAIN-COMPARE Investigators. Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. *Circ Cardiovasc Interv* 2009;**2**:167–177.
61. Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Ej West N, Piek JJ, Zaman A, Fath-Ordoubadi F, Stables RH, Appleby C, van Mieghem N, van Geuns RJ, Uren N, Zueco J, Buszman P, Iniguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, Hanratty C, Cavalcante R, Kappetein AP, Taggart DP, van Es GA, Morel MA, de Vries T, Onuma Y, Farooq V, Serruys PW, Banning AP. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. *Eur Heart J* 2017;**38**:3124–3134.